Skip to main content
SpringerLink
Log in

Can We Ensure the Safe Use of Known Human Teratogens?

Introduction of Generic Isotretinoin in the US as an Example

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The prescription of known teratogenic medications requires a careful balance between allowing women access to medications that they might need and avoiding unnecessary exposure to these medications during pregnancy because of their devastating fetal effects. Isotretinoin, a potent human teratogen, is of particular concern because of its widespread use among reproductive-aged women and the dramatic increase in use from 1992 through 2000. A revised risk management system was implemented in 2002 because of concerns about the continued occurrence of isotretinoin-exposed pregnancies. However, the recent approval of three generic versions of isotretinoin in the US has further complicated risk management and raises concerns that use might increase further if the lower cost of generics serves to increase accessibility. There are now four separate isotretinoin risk management systems in the US, each with its own distinct packaging, though the requirements for and substance of each are identical. Some additional concrete steps could be taken to minimise any unnecessary use of isotretinoin and help allow an adequate assessment of the current risk management systems. In addition to being familiar with and following all aspects of the current risk management system, physicians could choose to limit the use of isotretinoin to those who meet the labelled indications in order to reduce the number of exposed pregnancies. All four companies currently marketing isotretinoin in the US could jointly and voluntarily establish a consolidated, mandatory registration and follow-up of all women of reproductive potential who receive an isotretinoin prescription. Mandatory registration has many challenges, but it could allow a clear accounting of the total number of women for whom follow-up information is and is not available. Although the companies cannot be legally compelled to use a consolidated approach, the use of a single registry for the originator’s product and all generic brands would allow identification of duplicates and also avoid the confusion that is introduced by providing materials that not only look different, but also have different addresses, contact information and names for participation in follow-up surveys. This is particularly important because women might take more than one version of isotretinoin during a single course of therapy or might receive a different programme’s materials from their doctor than from the pharmacy. Though the introduction of generic versions of isotretinoin further complicates risk management, the companies marketing isotretinoin have an opportunity to work together to demonstrate their commitment to both limit the occurrence of exposed pregnancies and conduct a meaningful evaluation of the occurrence of pregnancies exposed to isotretinoin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology 1978; 17: 353–8

    Article  PubMed  CAS  Google Scholar 

  2. Leck IM, Millar ELM. Incidence of malformations since the introduction of thalidomide. BMJ 1962; 2: 16–20

    Article  PubMed  CAS  Google Scholar 

  3. Lenz W. Malformations caused by drugs in pregnancy. Am J Dis Child 1966; 112: 99–106

    PubMed  CAS  Google Scholar 

  4. Shepard TH. Teratogenicity from drugs: an increasing problem. Dis Mon 1974, 1–32

    Google Scholar 

  5. Rubin JD, Ferencz C, Loffredo C, et al. Use of prescription and non-prescription drugs in pregnancy. J Clin Epidemiol 1993; 46(6): 581–9

    Article  PubMed  CAS  Google Scholar 

  6. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191(2): 398–407

    Article  PubMed  Google Scholar 

  7. Piper JM, Baum C, Kennedy DL. Prescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol 1987; 157: 148–56

    PubMed  CAS  Google Scholar 

  8. Piper JM, Mitchel EF. Prenatal exposure to prescribed drugs in Tennessee Medicaid, 1983-1988. Paediatr Perinat Epidemiol 1991; 5: 402–9

    Article  PubMed  CAS  Google Scholar 

  9. Splinter MY, Sagraves R, Nightengale B, et al. Prenatal use of medications by women giving birth at a university hospital. South Med J 1997; 90(5): 498–502

    Article  PubMed  CAS  Google Scholar 

  10. Berthier M, Bonneau D, Perault MC, et al. Medications exposure during pregnancy. Therapie 1993; 48: 43–6

    PubMed  CAS  Google Scholar 

  11. Piper JM, Baum C, Kennedy DL. Maternal use of prescribed drugs associated with recognized fetal adverse drug reactions. Am J Obstet Gynecol 1988; 159: 1173–7

    PubMed  CAS  Google Scholar 

  12. Olesen C, Sorensen HT, De Jong-van den Berg L, et al. Prescribing during pregnancy and lactation with reference to the Swedish classification system: a population-based study among Danish women. Acta Obstet Gynecol Scand 1999; 78: 686–92

    Article  PubMed  CAS  Google Scholar 

  13. Malm H, Martikainen J, Klaukka T, et al. Prescription of hazardous drugs during pregnancy. Drug Safety 2004; 27(12): 899–908

    Article  PubMed  Google Scholar 

  14. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol 2004; 18(2): 106–11

    Article  PubMed  Google Scholar 

  15. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132–8

    Article  PubMed  CAS  Google Scholar 

  16. Olesen C, Thrane N, Lauge Nielsen G, et al. A population-based prescription study of asthma drugs during pregnancy: changing the intensity of asthma therapy and perinatal outcomes. Respiration 2001; 68: 256–61

    Article  PubMed  CAS  Google Scholar 

  17. UNICEF. A league table of teenage births in rich nations [Innocenti report card no. 3]. Florence: UNICEF Innocenti Research Centre, 2001 Jul

  18. Henshaw SK. Unintended pregnancy in the United States. Fam Plan Perspect 1998; 30: 24–9, 46

    Article  CAS  Google Scholar 

  19. De Santis M, Carducci B, Cavaliere AF, et al. Drug-induced congenital defects: strategies to reduce the incidence. Drug Saf 2001; 24: 889–901

    Article  PubMed  Google Scholar 

  20. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837–41

    Article  PubMed  CAS  Google Scholar 

  21. McBride WG. Thalidomide embryopathy. Teratology 1977; 16: 79–82

    Article  PubMed  CAS  Google Scholar 

  22. Newman CGH. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 1986; 13: 555–73

    PubMed  CAS  Google Scholar 

  23. Hall J, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122–40

    Article  PubMed  CAS  Google Scholar 

  24. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; ll: 937

    Article  Google Scholar 

  25. Lammer EJ, Sever LE, Oakley Jr GP. Teratogen update: valproic acid. Teratology 1987; 35: 465–73

    Article  PubMed  CAS  Google Scholar 

  26. Kelly TE. Teratogenicity of anticonvulsant drugs: I. Review of the literature. Am J Med Genet 1984; 19: 413–34

    Article  PubMed  CAS  Google Scholar 

  27. Kelly TE. Teratogenicity of anticonvulsant drugs. II: a prospective study. Am J Med Genet 1984; 19: 435–43

    Article  PubMed  CAS  Google Scholar 

  28. Barr Jr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994; 50: 399–409

    Article  PubMed  CAS  Google Scholar 

  29. Honein MA, Paulozzi LJ, Erickson JD. Continued occurrence of Accutane®-exposed pregnancies. Teratology 2001; 64: 142–7

    Article  PubMed  CAS  Google Scholar 

  30. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002; 46: 505–9

    Article  PubMed  Google Scholar 

  31. Cunliffe WJ, van de Kerkhof PCM, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351–7

    Article  PubMed  CAS  Google Scholar 

  32. Rafshoon E. What price beauty? Boston Globe Magazine 2003 Apr 27: 15

  33. Findlay SD. Direct-to-consumer promotion of prescription drugs: economic implications for patients, payers, and providers. Pharmacoeconomics 2001; 19(2): 109–19

    Article  PubMed  CAS  Google Scholar 

  34. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA 1999; 281: 380–2

    Article  PubMed  CAS  Google Scholar 

  35. Hollon MF. Direct-to-consumer marketing of prescription drugs: creating consumer demand. JAMA 1999; 281: 382–4

    Article  PubMed  CAS  Google Scholar 

  36. Gillmor P. lssues relating to the safety of Accutane: hearing before the subcommittee on oversight and investigations of the committee on energy and commerce. US House of Representatives, 107th Congress, 2nd session, 12/11/2002 [online]. Available from URL: http://energycommerce.house.gov/107/action/107-143.pdf [Accessed 2003 Jun 24]

  37. Stern RS. When a uniquely effective drug is teratogenic: the case of isotretinoin. N Engl J Med 1989; 320(15): 1007–9

    Article  PubMed  CAS  Google Scholar 

  38. Daniel KL, Honein MA, Moore CA. Sharing prescription medication among teenage girls: potential danger to unplanned/undiagnosed pregnancies. Pediatrics 2003; 111: 1167–70

    PubMed  Google Scholar 

  39. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333(2): 101–6

    Article  PubMed  CAS  Google Scholar 

  40. Moos MK, Petersen R, Meadows K, et al. Pregnant women’s perspectives on intendedness of pregnancy. Womens Health Issues 1997; 7(6): 385–92

    Article  PubMed  CAS  Google Scholar 

  41. Brown S. Issues relating to the safety of Accutane: hearing before the subcommittee on oversight and investigations of the committee on energy and commerce. US House of Representatives, 107th Congress, 2nd session, 12/11/2002 [online]. Available from URL: http://energycommerce.house.gov/107/action/107-143.pdf [Accessed 2003 Jun 24]

  42. Ortonne JP. Oral isotretinoin treatment policy: do we all agree? Dermatology 1997; 195Suppl. 1: 34–7

    Article  PubMed  Google Scholar 

  43. Doering PL, Araujo OE, Frohnapple DJ, et al. Patterns of prescribing isotretinoin: focus on women of childbearing potential. Ann Pharmacother 1992; 26: 155–61

    PubMed  CAS  Google Scholar 

  44. Cooper AJ, on behalf of the Australian Roaccutane Advisory Board. Treatment of acne with isotretinoin: recommendations based on the Australian experience. Australas J Dermatol 2003; 44: 97–105

    Article  PubMed  Google Scholar 

  45. Li VW, Jaffe MP, Li WW, et al. Off-label dermatologic therapies: usage, risks, and mechanisms. Arch Dermatol 1998; 134(11): 1449–54

    Article  PubMed  CAS  Google Scholar 

  46. Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992; 26: 931–5

    Article  PubMed  CAS  Google Scholar 

  47. Stern RS. Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol 2000; 43(6): 1042–8

    Article  PubMed  CAS  Google Scholar 

  48. Wert S. Identification and management of oral isotretinoin use inconsistent with product labeling. Manag Care Interface 2003; 16(3): 41–3, 55

    PubMed  Google Scholar 

  49. Greenwood J. Issues relating to the safety of Accutane: hearing before the subcommittee on oversight and investigations of the committee on energy and commerce. US House of Representatives, 107th Congress, 2nd session, 12/11/2002 [online]. Available from URL: http://energycommerce.house.gov/107/action/107-143.pdf [Accessed 2003 Jun 24]

  50. Shenefelt RE. Morphogenesis of malformations in hamsters caused by retinoic acid: relation to dose and stage at treatment. Teratology 1972; 5: 103–18

    Article  PubMed  CAS  Google Scholar 

  51. Kochhar DM. Teratogenic activity of retinoic acid. Acta Pathol Microbiol Scand 1967; 70: 398–404

    Article  PubMed  CAS  Google Scholar 

  52. Fantel AG, Shepard TG, Newell-Morris LL, et al. Teratogenic effects of retinoic acid in pigtail monkeys (Macaca nemestrina). 1: general features. Teratology 1977; 15: 65–71

    Article  PubMed  CAS  Google Scholar 

  53. Hansen LA, Pearl GS. Isotretinoin teratogenicity. Acta Neuropathol 1985; 65: 335–7

    Article  PubMed  CAS  Google Scholar 

  54. Rappaport EB, Knapp M. Isotretinoin embryopathy: a continuing problem. J Clin Pharmacol 1989; 29: 463–5

    PubMed  CAS  Google Scholar 

  55. Mitchell AA, Van Bennekom CM. Survey of Accutane use in women: briefing materials provided to the FDA Dermatologic and Ophthalmic Drugs Advisory Committee, 8/28/2000 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3639b1c/c_24.pdf [Accessed 2003 Jun 24]

  56. Coberly S, Lammer E. Retinoic acid embryopathy: case report and review of literature. Pediatr Pathol Lab Med 1996; 16: 823–36

    Article  PubMed  CAS  Google Scholar 

  57. Lowenstein EJ. Isotretinoin made S.M.A.R.T. and simple. CUTIS 2002; 70: 115–20

    PubMed  Google Scholar 

  58. Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21(2): 319–30

    Article  PubMed  CAS  Google Scholar 

  59. Clark TE, Edom N, Larson J, et al. Thalomid (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 2001; 24(2): 87–117

    Article  PubMed  CAS  Google Scholar 

  60. Uhl K. Proceedings of the FDA Joint Drug Safety and Risk Management & Dermatologic and Ophthalmic Drugs Advisory Committee Meeting; 2004 Feb 26–27; Gaithersburg (MD). Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4017T2.htm [Accessed 2004 Sep 22]

    Google Scholar 

  61. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6 year experience. Arch Neurol 2004; 61(5): 673–8

    Article  PubMed  Google Scholar 

  62. Uhl K, Kennedy DL, Kweder SL. Risk management strategies in the physicians’ desk reference product labels for pregnancy category X drugs. Drug Saf 2002; 25(12): 885–92

    Article  PubMed  Google Scholar 

  63. Pastuszak A, Koren G, Rieder MJ. Use of the retinoid pregnancy prevention program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate. Reprod Toxicol 1994; 8(1): 63–8

    Article  PubMed  CAS  Google Scholar 

  64. Atanackovic G, Koren G. Fetal exposure to isotretinoin: failure to comply with the Pregnancy Prevention Program. CMAJ 1999; 160(12): 1719–20

    PubMed  CAS  Google Scholar 

  65. Hatcher L. Who’s heard of the pregnancy prevention program? [letter]. Can Fam Physician 1999; 45: 871

    PubMed  CAS  Google Scholar 

  66. James M. Isotretinoin for severe acne. Lancet 1996; 347(9017): 1749–50

    Article  PubMed  CAS  Google Scholar 

  67. Källén B. Restriction of the use of drugs with teratogenic properties: Swedish experiences with isotretinoin [letter]. Teratology 1999; 60: 53

    Article  PubMed  Google Scholar 

  68. Australasian College of Dermatologists. Acne [online]. Available from URL: http://www.dermcoll.asn.au/Images/skin_a-z/pdfs/acne.pdf [Accessed 2003 Jun 25]

  69. Parliament of Ireland. Parliamentary debates (Dáil and Seanad) 1999 official report. September 1999 [online]. Available from URL: http://www.irlgov.ie/debates-99/30sep99/sect10.htm [Accessed 2003 Jun 4]

  70. Anonymous. Health plans keeping drug cost increases in check with programs to promote generics. Capitation Manag Rep 2002; 9 (7): 101–3, 97

  71. Suh DC, Manning Jr WG, Schondelmeyer S, et al. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Serv Res 2000; 35(2): 529–47

    PubMed  CAS  Google Scholar 

  72. Grabowski H, Vernon J. Longer patents for increased generic competition in the US: the Waxman-Hatch Act after one decade. Pharmacoeconomics 1996; 10Suppl. 2: 110–23

    Article  PubMed  Google Scholar 

  73. Hollis A. The importance of being first: evidence from Canadian generic pharmaceuticals. Health Econ 2002; 11: 723–34

    Article  PubMed  Google Scholar 

  74. Sisto FR. Proceedings of the FDA Joint Drug Safety and Risk Management & Dermatologic and Ophthalmic Drugs Advisory Committee Meeting; 2004 Feb 26–27; Gaithersburg (MD). Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4017T1.htm [Accessed 2004 Sep 22]

    Google Scholar 

  75. Huber MH. Proceedings of the FDA Joint Drug Safety and Risk Management & Dermatologic and Ophthalmic Drugs Advisory Committee Meeting; 2004 Feb 26–27; Gaithersburg (MD). Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4017T1.htm [Accessed 2004 Sep 22]

    Google Scholar 

  76. American Academy of Dermatology Association (AAD). Government affairs, 12/9/02 [online]. Available from URL: http://www.aadassociation.org/Isotretinoin_update.html [Accessed 2003 May 20]

  77. Europharmacy [online]. Available from URL: http://www.europharmacy.com/orderform/skincare [Accessed 2003 May 29]

  78. CVS/pharmacy [online]. Available from URL: http://www.CVS.com [Accessed 2003 Jun 27]

  79. Food and Drug Administration (FDA). Important consumer safety A.L.E.R.T. [online]. Available from URL: http://www.fda.gov/buyonline/consumerA.L.E.R.T.120902.html [Accessed 2003 May 23]

  80. Proceedings of the FDA Joint Drug Safety and Risk Management & Dermatologic and Ophthalmic Drugs Advisory Committee Meeting, 2004 Feb 26-27; Gaithersburg (MD). Available from URL: http://www.fda.gov/oc/advisory/accalendar/2004fcder12535dd02262704.html [Accessed 2004 Sep 23]

Download references

Acknowledgements

This study was funded by the Centers for Disease Control and Prevention. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop E-86, Atlanta, NE, GA, 30333, USA

    Margaret A. Honein, Cynthia A. Moore & J. David Erickson

Authors
  1. Margaret A. Honein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cynthia A. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. David Erickson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Honein, M.A., Moore, C.A. & Erickson, J.D. Can We Ensure the Safe Use of Known Human Teratogens?. Drug-Safety 27, 1069–1080 (2004). https://doi.org/10.2165/00002018-200427140-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427140-00001

Keywords

Search

Navigation